Intra-Cellular Therapies, Inc. (ITCI) | Investment Case

1. Company Snapshot

1.a. Company Description

Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States.The company offers CAPLYTA for the treatment of schizophrenia in adults.It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders.

In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety.Intra-Cellular Therapies, Inc.was founded in 2002 and is headquartered in New York, New York.

Show Full description

1.b. Last Insights on ITCI

Intra-Cellular Therapies' recent strength is driven by its Q4 earnings report, which topped revenue estimates. The company reported a quarterly loss of $0.16 per share, compared to a loss of $0.30 per share a year ago. A recent settlement of Caplyta patent litigation with Sandoz protects the drug's exclusivity in the US until 2040, and a potential acquisition by Johnson & Johnson for $132.00 per share is being investigated by law firms for fairness to shareholders.

1.c. Company Highlights

Last Price	131.87
Change Percentage	0.00%
Open	131.87
Previous Close	131.87
Market Cap ( Millions)	14047
Volume	16042154
Year High	131.98
Year Low	64.09
M A 50	129.42
M A 200	92.67

FCF Yield	-0.28%
Dividend Yield	0.00%
ROE	-5.19%
Debt / Equity	1.48%
Net Debt / EBIDTA	303.53%
Price To Book	11.84
Price Earnings Ratio	-228.84
Price To FCF	-356.68
Price To sales	26.22
EV / EBITDA	-144.01

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

May -01

Source: globenewswire.com

ITCI Q4 Loss Wider Than Expected, Revenues Top on Higher Caplyta Sales

Feb -24

Source: zacks.com

Intra-Cellular Therapies (ITCI) Reports Q4 Loss, Tops Revenue Estimates

Feb -21

Source: zacks.com

Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2024 Financial Results

Feb -21

Source: globenewswire.com

Healthy Returns: Biotech and pharma M&A is off to a good start in 2025 — but will it last?

Jan -21

Source: cnbc.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ENFN and ITCI on Behalf of Shareholders

Jan -16

Source: prnewswire.com

Intra-Cellular Therapies Stock Up 34% on J&J's $14.6B Buyout Offer

Jan -14

Source: zacks.com

Intra-Cellular (ITCI) Moves 34.1% Higher: Will This Strength Last?

Jan -14

Source: zacks.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (9.27%)

6. Segments

Small Molecule Drugs

Expected Growth: 9.27%

Intra-Cellular Therapies' small molecule drugs exhibit 9.27% growth driven by increasing demand for novel treatments in psychiatry and neuroscience, strong pipeline of candidates in Phase II and III clinical trials, and strategic partnerships for commercialization and development. Additionally, the company's focus on underserved markets and innovative formulations contribute to its growth momentum.

7. Detailed Products

Caplyta

Caplyta is a prescription medicine used to treat depressive episodes in adults with bipolar I disorder. It is also used to treat schizophrenia in adults.

lumateperone

Lumateperone is an investigational drug being developed for the treatment of major depressive disorder, bipolar depression, and other psychiatric conditions.

ITI-1284

ITI-1284 is an investigational drug being developed for the treatment of agitation in patients with dementia, including Alzheimer's disease.

ITI-007

ITI-007 is an investigational drug being developed for the treatment of schizophrenia, bipolar disorder, and other psychiatric conditions.

8. Intra-Cellular Therapies, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Intra-Cellular Therapies, Inc. has a moderate threat of substitutes due to the presence of alternative treatments and therapies for mental health disorders.

Bargaining Power Of Customers

The bargaining power of customers is low due to the specialized nature of Intra-Cellular Therapies, Inc.'s products and the lack of alternative options for patients.

Bargaining Power Of Suppliers

The bargaining power of suppliers is moderate due to the presence of multiple suppliers for raw materials and the company's dependence on these suppliers.

Threat Of New Entrants

The threat of new entrants is high due to the growing demand for mental health treatments and the increasing interest in psychedelic-based therapies.

Intensity Of Rivalry

The intensity of rivalry is high due to the presence of established players in the mental health industry and the increasing competition for market share.

9. SWOT Analysis

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

	Value
Debt Weight	2.78%
Debt Cost	3.95%
Equity Weight	97.22%
Equity Cost	8.97%
WACC	8.83%
Leverage	2.86%

11. Quality Control: Intra-Cellular Therapies, Inc. passed 4 out of 9 key points

Strong Liquidity

Low Debt

Strong Interest Coverage

Healthy Cash Flow

Operating Efficiency

Strong Return On Equity

Consistent Revenue Growth

Consistent Operating Cash Flow Growth

Margin Improvement

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Intra-Cellular Therapies

A-Score: 5.3/10

Value: 6.0

Growth: 7.1

Quality: 5.1

Yield: 0.0

Momentum: 10.0

Volatility: 3.3

1-Year Total Return ->

Elanco Animal Health

A-Score: 4.6/10

Value: 3.9

Growth: 6.0

Quality: 5.1

Yield: 0.0

Momentum: 8.5

Volatility: 4.3

1-Year Total Return ->

Amneal Pharmaceuticals

A-Score: 4.4/10

Value: 3.9

Growth: 3.7

Quality: 6.0

Yield: 0.0

Momentum: 7.5

Volatility: 5.3

1-Year Total Return ->

Lantheus Holdings

A-Score: 4.2/10

Value: 5.8

Growth: 9.0

Quality: 7.9

Yield: 0.0

Momentum: 0.0

Volatility: 2.7

1-Year Total Return ->

Deciphera Pharmaceuticals

A-Score: 3.9/10

Value: 6.2

Growth: 6.1

Quality: 5.0

Yield: 0.0

Momentum: 5.0

Volatility: 1.0

1-Year Total Return ->

Catalent

A-Score: 3.0/10

Value: 3.2

Growth: 2.2

Quality: 1.8

Yield: 0.0

Momentum: 6.0

Volatility: 5.0

1-Year Total Return ->

Peers Metrics

12.e Scoring ^Insights

12.f DCF ^BETA

Parameters

Short Term Growth

60.78%

Short term Time

10.0

Long-Term Growth

2.00%

WACC

8.83%

Intra-Cellular Therapies, Inc. - US46116X1019

1. Company Snapshot

1.a. Company Description

1.b. Last Insights on ITCI

1.c. Company Highlights

Higher Growth

Medium Volatility

Stable Momentum

Earnings Beats

Revenues Beats

Average Growth

Strong Momentum

Average Yield

Earnings Miss

Revenues Miss

Less Volatile

2. Transcript Summary

3. NewsRoom

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (9.27%)

6. Segments

Small Molecule Drugs

Expected Growth: 9.27%

7. Detailed Products

Caplyta

lumateperone

ITI-1284

ITI-007

8. Intra-Cellular Therapies, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Bargaining Power Of Customers

Bargaining Power Of Suppliers

Threat Of New Entrants

Intensity Of Rivalry

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

11. Quality Control: Intra-Cellular Therapies, Inc. passed 4 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

131.87$

Current Price

131.87$

Potential

-0.00%

Expected Cash-Flows

12.e Scoring ^Insights

12.f DCF ^BETA